BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $2,929,000 | +88.4% | 45,599 | +127.4% | 0.33% | +80.9% |
| Q1 2022 | $1,555,000 | +251.0% | 20,049 | +288.5% | 0.18% | +273.5% |
| Q4 2021 | $443,000 | -83.9% | 5,160 | -84.9% | 0.05% | -82.3% |
| Q2 2021 | $2,753,000 | +398.7% | 34,198 | +396.7% | 0.28% | +211.2% |
| Q4 2020 | $552,000 | +19.7% | 6,885 | +20.1% | 0.09% | +20.3% |
| Q3 2020 | $461,000 | -36.2% | 5,735 | -31.7% | 0.07% | -32.1% |
| Q2 2020 | $723,000 | -42.1% | 8,400 | -48.2% | 0.11% | -37.0% |
| Q3 2018 | $1,249,000 | +106.4% | 16,203 | +74.0% | 0.17% | +92.2% |
| Q1 2018 | $605,000 | +22.5% | 9,314 | +22.0% | 0.09% | +2.3% |
| Q4 2017 | $494,000 | +42.8% | 7,633 | +37.9% | 0.09% | +57.1% |
| Q3 2017 | $346,000 | +24.5% | 5,535 | +20.9% | 0.06% | +7.7% |
| Q2 2017 | $278,000 | -31.2% | 4,580 | -49.7% | 0.05% | -51.9% |
| Q4 2016 | $404,000 | -25.2% | 9,102 | -30.8% | 0.11% | -26.0% |
| Q1 2016 | $540,000 | +158.4% | 13,145 | +104.8% | 0.15% | +105.6% |
| Q3 2015 | $209,000 | -16.4% | 6,418 | +86.0% | 0.07% | -78.0% |
| Q2 2014 | $250,000 | -35.6% | 3,451 | -41.5% | 0.32% | -51.4% |
| Q3 2013 | $388,000 | – | 5,900 | – | 0.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |